Overview

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Phase I Dose Finding Study for GQ1001 in Patients with HER2-Positive Advanced Solid Tumors
Phase:
Phase 1
Details
Lead Sponsor:
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Collaborator:
CRC Oncology